US 12,144,869 B2
Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates
Amandeep Gakhal, San Mateo, CA (US); Abigail Yu, San Jose, CA (US); Ryan Stafford, Foster City, CA (US); Jeffrey Hanson, Oakland, CA (US); Alice Yam, Belmont, CA (US); Krishna Bajjuri, Union City, CA (US); Andreas Maderna, Walnut Creek, CA (US); Cristina Abrahams, Burlingame, CA (US); Xiaofan Li, Belmont, CA (US); Gang Yin, South San Francisco, CA (US); Miao Wen, Union City, CA (US); Kristin Bedard, Bellevue, WA (US); Daniel Calarese, Millbrae, CA (US); and Helena Kiefel, South San Francisco, CA (US)
Assigned to SUTRO BIOPHARMA, INC., South San Francisco, CA (US)
Filed by Sutro Biopharma, Inc., South San Francisco, CA (US)
Filed on Jun. 30, 2023, as Appl. No. 18/345,892.
Claims priority of provisional application 63/495,635, filed on Apr. 12, 2023.
Claims priority of provisional application 63/489,926, filed on Mar. 13, 2023.
Claims priority of provisional application 63/487,706, filed on Mar. 1, 2023.
Claims priority of provisional application 63/382,262, filed on Nov. 3, 2022.
Claims priority of provisional application 63/389,741, filed on Jul. 15, 2022.
Claims priority of provisional application 63/357,442, filed on Jun. 30, 2022.
Prior Publication US 2024/0058465 A1, Feb. 22, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/68 (2017.01); A61K 31/502 (2006.01); A61P 35/00 (2006.01)
CPC A61K 47/6869 (2017.08) [A61K 31/502 (2013.01); A61K 47/6803 (2017.08); A61K 47/6805 (2017.08); A61K 47/6809 (2017.08); A61K 47/6849 (2017.08); A61K 47/6889 (2017.08); A61P 35/00 (2018.01)] 24 Claims
 
1. A conjugate comprising an antibody that specifically binds to receptor tyrosine kinase orphan receptor 1 (ROR1), the antibody being linked site-specifically to at least one payload moiety and comprising one or more non-natural amino acids and:
(a) (i) a VH region comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 4 and 171; a CDR-H2 comprising at least one of SEQ ID NOs: 338 and 505; and a CDR-H3 comprising SEQ ID NO: 672; and (ii) a VL comprising: a CDR-L1 comprising SEQ ID NO: 839; a CDR-L2 comprising SEQ ID NO: 844; and a CDR-L3 comprising SEQ ID NO: 849;
(b) (i) a VH region comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 9 and 176; a CDR-H2 comprising at least one of SEQ ID NOs: 343 and 510; and a CDR-H3 comprising SEQ ID NO: 677; and (ii) a VI region comprising: a CDR-L1 comprising SEQ ID NO: 839; a CDR-L2 comprising SEQ ID NO: 844; and a CDR-L3 comprising SEQ ID NO: 849; or
(c) (i) a VH region comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 45 and 212; a CDR-H2 comprising at least one of SEQ ID NOs: 379 and 546; and a CDR-H3 comprising SEQ ID NO: 713; and (ii) a VI region comprising: a CDR-L1 comprising SEQ ID NO: 839; a CDR-L2 comprising SEQ ID NO: 844; and a CDR-L3 comprising SEQ ID NO: 849.